Evidence map›Paper›PMID 35454146›Full record

ArticleBiomolecules2022

Clinical Role of Serum miR107 in Type 2 Diabetes and Related Risk Factors.

Diana Šimonienė, Darius Stukas, Albertas Daukša, Džilda Veličkienė

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Diana ŠimonienėDepartment of Endocrinology, Lithuanian University of Health Sciences (LUHS), 50161 Kaunas, Lithuania.
Darius StukasLaboratory of Surgical Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences (LUHS), 44307 Kaunas, Lithuania.
Albertas DaukšaLaboratory of Surgical Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences (LUHS), 44307 Kaunas, Lithuania.
Džilda VeličkienėDepartment of Endocrinology, Lithuanian University of Health Sciences (LUHS), 50161 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs the diagnostic and treatment options for diabetes improve, more attention nowadays is being paid to the exact identification of the etiopathological mechanism of type 2 diabetes (T2DM). Insulin resistance (IR) is a pathogenetic background for T2DM. Several studies demonstrate that miRNAs play an important role in systemic inflammation and thus in T2DM pathogenesis. Overexpression of miR-107 may cause an imbalance of glucose homeostasis, obesity, and dyslipidemia, by regulating insulin sensitivity through the insulin signaling pathway.

methods53 patients with T2DM and 54 nondiabetic patients were involved in the study. This study aimed to examine whether miR-107 expression in the serum of patients with diabetes was different from the control group (non-diabetic) and whether miR-107 expression correlated with lipid levels, BMI, and other factors, and finally, with insulin resistance in general.

resultsmiR-107 expression was higher in the T2DM group than in the control group (1.33 versus 0.63 (

conclusionMiR-107 expression is higher among diabetic patients than that of nondiabetic control subjects. Higher miR-107 levels are also related to dyslipidemia (lower HDL levels)-in the general cohort and non-diabetic subjects. Moreover, higher miR-107 expression is related to insulin resistance in the diabetic group. In general, higher miR-107 expression levels are related to a higher BMI, older age, and the male gender.

Indexed as

Diabetes Mellitus, Type 2DyslipidemiasInsulin ResistanceMicroRNAsBlood GlucoseFemaleHumansInsulinMaleRisk FactorsBlood GlucoseInsulinMicroRNAsMIRN107 microRNA, humaninsulin resistance 1miR-107type 2 diabetes 2

Identifiers

PMID35454146
PMCPMC9027608
OpenAlexW4224292232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.